Prothena Corporation PLC

PRTA remains in a Stage 4 decline with a clear lower-high/lower-low sequence and price trading below its major moving averages. The recent short-covering rally has pushed price into declining 9/21/50 EMAs and verging on resistance at the 200DMA, creating an opportune zone to trim bearish positions. With medium- and long-term trends firmly down and overbought short-term indicators, fading this rally into moving-average resistance aligns with the prevailing downtrend.

• ↑Pipeline’s PRX-12 and Bertamumab anticipate top-line results Q4’24–Q2’25.
• ↑Closed Q4’23 with $621M cash, extending runway for pivotal trials into 2025.
• ↓2024 op cash burn estimated at $208–225M strains liquidity runway.